NASDAQ:TRDA Entrada Therapeutics (TRDA) Stock Price, News & Analysis $7.46 +0.01 (+0.13%) Closing price 08/14/2026 04:00 PM EasternExtended Trading$7.47 +0.01 (+0.13%) As of 08/14/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Entrada Therapeutics Stock (NASDAQ:TRDA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Entrada Therapeutics alerts:Sign Up Key Stats Today's Range$7.21▼$7.5350-Day Range$5.83▼$7.7452-Week Range$5.02▼$16.45Volume237,985 shsAverage Volume446,610 shsMarket Capitalization$290.47 millionP/E RatioN/ADividend YieldN/APrice Target$17.75Consensus RatingModerate Buy Company Overview Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs. The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity. Lead programs target lysosomal storage disorders and neuromuscular diseases, with preclinical candidates optimized for tissue tropism and intracellular uptake. Entrada’s technology is designed to be modular, allowing for potential application across multiple therapeutic areas. Founded in Cambridge, Massachusetts, Entrada leverages a team with expertise in protein engineering, cell biology and drug delivery. The company serves patients globally by pursuing regulatory filings in key markets and collaborating with academic partners and contract development organizations. Through continued platform development and strategic partnerships, Entrada seeks to bring novel intracellular therapies from lab to clinic.AI Generated. May Contain Errors. Read More Entrada Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreTRDA MarketRank™: Entrada Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 311th out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingEntrada Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialEntrada Therapeutics has a consensus price target of $17.75, representing about 137.9% upside from its current price of $7.46.Amount of Analyst CoverageEntrada Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Entrada Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Entrada Therapeutics are expected to grow in the coming year, from ($4.03) to ($3.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Entrada Therapeutics is -1.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Entrada Therapeutics is -1.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEntrada Therapeutics has a P/B Ratio of 1.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.08% of the float of Entrada Therapeutics has been sold short.Short Interest Ratio / Days to CoverEntrada Therapeutics has a short interest ratio ("days to cover") of 4.33.Change versus previous monthShort interest in Entrada Therapeutics has recently decreased by 3.90%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEntrada Therapeutics does not currently pay a dividend.Dividend GrowthEntrada Therapeutics does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.21 News SentimentEntrada Therapeutics has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Entrada Therapeutics this week, compared to 3 articles on an average week.Search Interest1 people have searched for TRDA on MarketBeat in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Entrada Therapeutics insiders have sold 10,564.92% more of their company's stock than they have bought. Specifically, they have bought $29,300.00 in company stock and sold $3,124,822.00 in company stock.Percentage Held by Insiders9.49% of the stock of Entrada Therapeutics is held by insiders.Percentage Held by Institutions86.39% of the stock of Entrada Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Entrada Therapeutics' insider trading history. Receive TRDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entrada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TRDA Stock News HeadlinesQ3 EPS Estimate for Entrada Therapeutics Lowered by AnalystAugust 14 at 1:28 AM | americanbankingnews.comEntrada Therapeutics (NASDAQ:TRDA) Major Shareholder Ventures L.P. 5Am Sells 10,494 Shares of StockAugust 11, 2026 | insidertrades.comThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits. | Porter & Company (Ad)Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Ventures L.P. 5Am Sells 52,317 SharesAugust 11, 2026 | americanbankingnews.comEntrada Therapeutics (NASDAQ:TRDA) Director Kush Parmar Sells 52,317 SharesAugust 11, 2026 | americanbankingnews.comEntrada Therapeutics (NASDAQ:TRDA) Director Kush Parmar Sells 92,444 Shares of StockAugust 11, 2026 | americanbankingnews.comEntrada Therapeutics Reports Second Quarter 2026 Financial ResultsAugust 5, 2026 | finance.yahoo.comInsider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $11,768.30 in StockAugust 4, 2026 | insidertrades.comSee More Headlines TRDA Stock Analysis - Frequently Asked Questions How have TRDA shares performed this year? Entrada Therapeutics' stock was trading at $10.28 at the start of the year. Since then, TRDA stock has decreased by 27.4% and is now trading at $7.46. How were Entrada Therapeutics' earnings last quarter? Entrada Therapeutics, Inc. (NASDAQ:TRDA) announced its quarterly earnings results on Wednesday, August, 5th. The company reported ($1.01) EPS for the quarter, missing analysts' consensus estimates of ($0.97) by $0.04. The firm earned $0.90 million during the quarter, compared to analyst estimates of $2.32 million. Entrada Therapeutics had a negative trailing twelve-month return on equity of 57.61% and a negative net margin of 3,537.73%. When did Entrada Therapeutics IPO? Entrada Therapeutics (TRDA) raised $182 million in an IPO on Thursday, October 28th 2021. The company issued 9,075,000 shares at $19.00-$21.00 per share. Who are Entrada Therapeutics' major shareholders? Entrada Therapeutics' top institutional shareholders include 5AM Venture Management LLC (10.42%), BlackRock Inc. (6.65%), GSA Capital Partners LLP (0.23%) and Bank of New York Mellon Corp (0.20%). Insiders that own company stock include Bros Advisors Lp Baker, Bioventures 2018 LP Mpm, Ventures V LP 5Am, Kush Parmar, Dipal Doshi, Natarajan Sethuraman, Nathan J Dowden, Kory James Wentworth, Peter S Kim and Bernhardt G Zeiher. View institutional ownership trends. How do I buy shares of Entrada Therapeutics? Shares of TRDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Entrada Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Entrada Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and Invesco QQQ (QQQ). Company Calendar Last Earnings8/05/2026Today8/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 TRDA's financial health is in the Red zone, according to TradeSmith. TRDA has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:TRDA CIK1689375 Webwww.entradatx.com Phone857-520-9158FaxN/AEmployees110Year Founded2016Price Target and Rating Average Price Target for Entrada Therapeutics$17.75 High Price Target$23.00 Low Price Target$11.00 Potential Upside/Downside+137.9%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($3.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$143.75 million Net Margins-3,537.73% Pretax Margin-3,520.25% Return on Equity-57.61% Return on Assets-46.54% Debt Debt-to-Equity RatioN/A Current Ratio10.89 Quick Ratio10.89 Sales & Book Value Annual Sales$4.69 million Price / Sales61.99 Cash FlowN/A Price / Cash FlowN/A Book Value$5.99 per share Price / Book1.25Miscellaneous Outstanding Shares38,937,000Free Float35,242,000Market Cap$290.47 million OptionableOptionable Beta-0.26 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:TRDA) was last updated on 8/16/2026 by MarketBeat.com Staff. From Our PartnersMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThe dollar just brokeBloomberg research shows the U.S. dollar's share of global reserves has fallen to the lowest level this centur...Porter & Company | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored"Second Wave” Hitting Iran Soon? Wall Street Issues WarningAnalysts at Goldman Sachs and Morgan Stanley are warning that a quiet domestic threat - unrelated to overseas ...TradeSmith | SponsoredRay Dalio: Buy Gold. Get Paid.Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...Investors Alley | SponsoredThe Greatest Wealth Transfer Since the Internet Boom Just StartedWall Street forensic accountant Joel Litman - who flagged the 2008 crash months early and called the 2020 COVI...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entrada Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
